Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
| Autor: | Min Ja Kim, Felix Glumcher, Hassan Gandjini, Antonio T. Freire, C. Angel Cooper, Nathalie Dartois, Oleksiy Datsenko, Yin Ching Chuang, Vasyl Melnyk, Oleksandr Dzyublik, Gary Dukart, Robert Maroko, Joan M. Korth-Bradley |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Microbiology (medical)
Imipenem medicine.medical_specialty Population Cilastatin Imipenem Drug Combination Minocycline Tigecycline Microbial Sensitivity Tests Glycylcycline Double-Blind Method Internal medicine polycyclic compounds medicine Humans Hospital Mortality education education.field_of_study Cross Infection Cilastatin business.industry Ventilator-associated pneumonia Imipenem/cilastatin Pneumonia Ventilator-Associated General Medicine Bacterial Infections Pneumonia bacterial infections and mycoses medicine.disease respiratory tract diseases Surgery Anti-Bacterial Agents Regimen Drug Combinations Infectious Diseases Treatment Outcome business medicine.drug |
| Zdroj: | Diagnostic microbiology and infectious disease. 68(2) |
| ISSN: | 1879-0070 |
| Popis: | To compare efficacy and safety of a tigecycline regimen with an imipenem/cilastatin regimen in hospital-acquired pneumonia patients, a phase 3, multicenter, randomized, double-blind, study evaluated 945 patients. Coprimary end points were clinical response in clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) populations at test-of-cure. Cure rates were 67.9% for tigecycline and 78.2% for imipenem (CE patients) and 62.7% and 67.6% (c-mITT patients), respectively. A statistical interaction occurred between ventilator-associated pneumonia (VAP) and non-VAP subgroups, with significantly lower cure rates in tigecycline VAP patients compared to imipenem; in non-VAP patients, tigecycline was noninferior to imipenem. Overall mortality did not differ between the tigecycline (14.1%) and imipenem regimens (12.2%), although more deaths occurred in VAP patients treated with tigecycline than imipenem. Overall, the tigecycline regimen was noninferior to the imipenem/cilastatin regimen for the c-mITT but not the CE population; this difference appears to have been driven by results in VAP patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect